Literature DB >> 30291566

Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1).

Roberta Vilela Lopes Koyama1, Gilberto Toshimitsu Yoshikawa2, Satomi Fujihara3, George Alberto da Silva Dias4, Rodrigo Rodrigues Virgolino3, Anderson Raiol Rodrigues3, Rita Medeiros3, Juarez Antônio Simões Quaresma3, Hellen Thaís Fuzii3.   

Abstract

This was a cross-sectional prospective study. We performed a multivariate statistical analysis of the neurological signs and symptoms of patients infected with human T cell lymphotropic virus type 1 (HTLV-1) in an attempt to separate them into distinct groups and identify clinical-neurological manifestations that could differentiate the various profiles. The study was performed in the city of Belém (state of Pará), located in the Amazon region of Brazil, from 2014 to 2016. We determined muscle strength and tone, reflexes, sensations, sphincter function, gait, and the Expanded Disability Status Scale score among individuals with HTLV-I. We then used exploratory statistical methods in an attempt to find different profiles and establish distinct groups. We analyzed 60 patients with HTLV-1. The filtering of the data, performed with mixed PCA, gave rise to a streamlined database with the most informative data and suggested the formation of three statistically distinct groups: asymptomatic carriers (AC), mono/oligosymptomatic (MOS), and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSPd), AC and MOS (p = 0.002), AC and HAM/TSPd (p < 0.001), and HAM/TSPd and MOS (p = 0.001). The subsequent cluster analysis confirmed the formation of three clusters. The classification and regression tree demonstrated that altered gait was the most important variable for the classification of an individual with HAM/TSPd and that, in the absence of this impairment, hyperreflexia characterized MOS. The present study was able to separate patients infected by HTLV-1 into three clinical groups (AC, HAM/TSPd, and MOS) and identify clinical manifestations that could differentiate the various patient groups.

Entities:  

Keywords:  Diagnoses and examinations; HAM/TSP; HTLV-I; HTLV-I-associated myelopathy; HTLV-I-associated myelopathy-tropical spastic paraparesis

Year:  2018        PMID: 30291566     DOI: 10.1007/s13365-018-0677-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  19 in total

1.  [HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study].

Authors:  Ana Paula Silva Champs; Valéria Maria de Azeredo Passos; Sandhi Maria Barreto; Luiz Sergio Vaz; João Gabriel Ramos Ribas
Journal:  Rev Soc Bras Med Trop       Date:  2010 Nov-Dec       Impact factor: 1.581

2.  Disability and determinants of gait performance in tropical spastic paraparesis/HTLV-I associated myelopathy (HAM/TSP).

Authors:  A C Franzoi; A Q C Araújo
Journal:  Spinal Cord       Date:  2006-03-28       Impact factor: 2.772

3.  Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM).

Authors:  Carlos M De Castro-Costa; Abelardo Q C Araújo; Márcio M Barreto; Osvaldo M Takayanagui; Marzia P Sohler; Eduardo L M da Silva; Sônia M B de Paula; Ricardo Ishak; João G R Ribas; Luis C Rovirosa; Herwig Carton; Eduardo Gotuzzo; William W Hall; Silvia Montano; Edward L Murphy; Joel Oger; Carlos Remondegui; Graham P Taylor
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

4.  Difficulties in HAM/TSP diagnosis.

Authors:  Carla Maria Sena Andrade Slater; Luiz Claudio Pereira Ribeiro; Marzia Puccioni-Sohler
Journal:  Arq Neuropsiquiatr       Date:  2012-09       Impact factor: 1.420

Review 5.  Human T-lymphotropic virus 1: recent knowledge about an ancient infection.

Authors:  Kristien Verdonck; Elsa González; Sonia Van Dooren; Anne-Mieke Vandamme; Guido Vanham; Eduardo Gotuzzo
Journal:  Lancet Infect Dis       Date:  2007-04       Impact factor: 25.071

6.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

7.  Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.

Authors:  Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby
Journal:  J Clin Virol       Date:  2011-03-08       Impact factor: 3.168

8.  Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis.

Authors:  E Gotuzzo; J Cabrera; L Deza; K Verdonck; A-M Vandamme; R Cairampoma; D Vizcarra; M Cabada; G Narvarte; C De las Casas
Journal:  Clin Infect Dis       Date:  2004-09-01       Impact factor: 9.079

9.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

10.  Clinical manifestations associated with HTLV type I infection: a cross-sectional study.

Authors:  Marina F Caskey; Daniel J Morgan; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Glória O Orge; Maria J Travassos; Yolanda Barrón; Edgar M Carvalho; Marshall J Glesby
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.